Navigation Links
Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Date:10/18/2007

Top Line Results of Phase II Study in Previous Nonresponders also Reported

KENILWORTH, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today provided an update on the clinical development program for boceprevir, its investigational oral hepatitis C protease inhibitor. Initial results from an ongoing Phase II study in treatment-naive (previously untreated) hepatitis C patients showed boceprevir (800 mg TID) in combination with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) achieved a high rate of early virologic response, with up to 79 percent of patients having undetectable virus (HCV-RNA) at week 12 of boceprevir treatment compared to 34 percent of patients receiving PEGINTRON and REBETOL alone.

"These initial results, while preliminary, are very encouraging, and showed that boceprevir is a potent antiviral agent for hepatitis C," said Paul Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, and the lead investigator of the study. "In this study, boceprevir improved viral clearance rates at week 12 in genotype 1 hepatitis C infection compared to the control group. We look forward to further results from this ongoing study."

Boceprevir is being evaluated in combination with PEGINTRON and REBETOL for the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1 in two large Phase II clinical studies, in which more than 800 patients have received boceprevir. One study involves treatment-naive patients and the other involves patients who were nonresponders to previous peginter
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
5. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
6. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
7. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Sygnis Pharma AG announces date for presentation of clinical results
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...RNewswire-FirstCall/ -- CEL-SCI Corporation,(NYSE:... Material Transfer,Agreement (MTA) with the Nation...d the laboratory of Dr. Francesco M. Marincola, M....to the tumor microenvironment,caused by CEL-SCI,s ...of,the Infectious Disease and Immunogentics Sectio...
(Date:10/7/2008)...Today at ACG Annual Scientific Meeting -, ORLANDO...Pharmaceuticals, Inc. (formerly Microbia, Inc.) an...nounced the presentation of results from a Phase,2...y in 420 patients with,irritable bowel syndrome wi...cates that once- daily oral dosing of linaclotide,...
(Date:10/7/2008)...lighting CIMZIA,s long-term benefits and value in,...ted at American College,of Gastroenterology (ACG),...ata from two studies,presented this week by UCB at...nual Meeting demonstrate that CIMZIA(R) (certolizu...mor Necrosis Factor alpha) - provides,sustained im...
(Date:10/7/2008)...rt Enrolled in Stage A of Trial Assessing Regimen ...and Paclitaxel -, TUSTIN, Calif., Oct. 7 /PRNewsw...(Nasdaq: PPHM ), a clinical stage biopharmaceutic...e treatment of cancer and,hepatitis C virus (HCV) ...nrollment in the first stage of a Phase II trial o...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 1deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 2deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 3deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 4deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 5So called sandfish could help materials handling and process technology specialists 5204 1So called sandfish could help materials handling and process technology specialists 5204 2So called sandfish could help materials handling and process technology specialists 5204 3Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 1Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 2Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 3Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 4Isolagen to Present at the JMP Securities Healthcare Focus Conference 8074 1Isolagen to Present at the JMP Securities Healthcare Focus Conference 8074 2
...0, 2007 - Australian,biotechnology company Avexa (... from its Phase IIb trial for apricitabine (ATC).,...ase inhibitor,(NRTI) being developed for the treat...ant HIV., The Phase IIb trial compared the effecti...ts with drug-resistant HIV with,the effectiveness ...
.../ -- Treatment of,coronary artery disease (CAD) ap...ng, according to a study published today in The,Am...on rates for heart attacks (acute myocardial,infar...ossibly due,to broader use of preventive treatment...lines in risk factors like smoking. , The study is...
Other Medicine Technology:Avexa Reports Positive Phase IIb Result 2Avexa Reports Positive Phase IIb Result 3Avexa Reports Positive Phase IIb Result 4Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
(Date:10/7/2008)...RNewswire-FirstCall/ -- Stallergenes S.A.,today an...greement with,Catalent for the promotion and distr...FLEX(R), co-developed and co-manufactured by Catal...sts of a syringe pre-filled with adrenaline, which....3 and 0.15 mg), in an,autoinjector device. The Me...
(Date:10/7/2008)...of asthma in a young child may well be more challe..., according to a review of research and clinical e... Indiana University School of Medicine and Riley H... issue of Clinical Pediatrics . , "Wheezing ca... Professor of Pediatrics at the IU School of Medic...
(Date:10/7/2008)...rial Specialties, Mfg. is pleased to announce the ...hese filters are exclusively available from Indust... push-to-connect style fittings integrated into th...ne filter offers versatility and customization for... (PRWEB) October 7, 2008 -- Exclusively availa...
(Date:10/6/2008)...fight against childhood obesity, researcher notes ... Three-quarters of middle schools have vending mac...new study finds. , The research demonstrates th...ls, and "that those vending machines don,t always ...y Virus, a registered dietitian with the Center fo...
Breaking Medicine News(10 mins):Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:Wheezing and asthma in young children 2Health News:Vending Machines Found in Most Middle Schools 2
...ing to recent update, people with type 2 diabetes ...emia) may be able to safely reduce their risk for ...ase niacin.// The finding runs counter to previous... blood sugar levels in diabetics. Certain studies,...
...ing to researchers, low body temperature, low insu...be linked to a slowdown of the aging process. It i...ses the lifespan of animals. Now researchers at th... about slowing down the aging process. They compar...
...ing to a new study, hospitals staffed with more re...- save more lives from deadly complications, and r...ify worries about the nation's growing nursing sho...s because we don't have the knowledge of the regis...
...study contributes to the findings of liver cancer....of Medicine report findings on a potential new tre...archers injected a compound called 3-bromopyruvate...cerous tumor. They say it did not adversely affect...
Other Medicine News:Health News:Nurses save more lives 2
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed.
The Neuroclip is designed for safe, quick, and stable fixation of cranial bone flaps. Application is simple with minimal instrumentation. The Neuroclip can be applied to the cranial bone flap while t
Lorenz 1.0 mm titanium system provides a rigid fixation alternative for areas with high palpability and prominent bone formation. These areas include the frontal bone and the areas surrounding the or
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery.
Medicine Products: